{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:50:15Z","timestamp":1792021815771,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacadv.2026.103129","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:34:22Z","timestamp":1786714462000},"page":"103129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction"],"prefix":"10.1016","volume":"5","author":[{"given":"Mohammed","family":"Essa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-2169","authenticated-orcid":false,"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica S.","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel R.","family":"Dajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mankbadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil F.","family":"Faridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jacadv.2026.103129_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"9753","key":"10.1016\/j.jacadv.2026.103129_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jacadv.2026.103129_bib3","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103129_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2026.103129_bib5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103129_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.jacadv.2026.103129_bib7","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","volume":"87","author":"Blumenthal Roger","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103129_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001429","article-title":"Clinical guidelines as a continuous work in progress: moving at the speed of science","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103129_bib9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103129_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103129_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101872","article-title":"Lipid-lowering therapy in the U.S. adults before and after the COVID-19 pandemic","volume":"4","author":"Essa","year":"2025","journal-title":"JACC Adv"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103129_bib12","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103129_bib13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jacadv.2026.103129_bib14","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jacc.2022.02.034","article-title":"The National Cardiovascular Data Registry Data Quality Program 2020","volume":"79","author":"Malenka","year":"2022","journal-title":"JACC"},{"issue":"19","key":"10.1016\/j.jacadv.2026.103129_bib15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.jacadv.2026.103129_bib16","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103129_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","article-title":"Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"24","author":"Hosseini","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacadv.2026.103129_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100491","article-title":"Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease","volume":"14","author":"Faridi","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"10059","key":"10.1016\/j.jacadv.2026.103129_bib19","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"10349","key":"10.1016\/j.jacadv.2026.103129_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103129_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s12872-024-04144-y","article-title":"The clinical effectiveness and safety of low\/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis","volume":"24","author":"Sydhom","year":"2024","journal-title":"BMC Cardiovasc Disord"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26005508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26005508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:26:55Z","timestamp":1792020415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26005508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772963X26005508"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103129","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103129"}}